Last updated: February 15, 2026
Product Identification
NDC 00093-2210 corresponds to Benztropine Mesylate, a medication primarily used to treat Parkinson’s disease and drug-induced parkinsonism.
Current Market Landscape
Benztropine Mesylate is available both as a branded and generic product, with the generic version dominating the market due to its lower price point. The drug is marketed in multiple formulations, including tablets and injectable forms.
Market Size and Demand Drivers
The demand for benztropine correlates with Parkinson's disease prevalence, which is approximately 1 million cases in the United States. The global Parkinson's market reached USD 3.9 billion in 2022, with anticholinergic therapies representing a subset.
Competitive Environment
Key competitors include generic manufacturers such as Teva, Mylan, and Sandoz. Branded options include Cogentin (by Valeant/Biovent). The market’s high generic availability exerts downward pressure on prices. Patent protections are largely expired, facilitating generic entry.
Pricing Dynamics
- Brand Name: Historically priced around USD 400–USD 600 per package (30 tablets).
- Generic: Prices vary by supplier but generally range from USD 10 to USD 30 per bottle of 30 tablets.
Recent Price Trends
- Generic prices have declined sharply over the past decade due to increased competition and manufacturing capacity.
- Wholesale acquisition costs (WACs) for generics have stabilized in 2023, averaging approximately USD 15–USD 20 per 30-tablet bottle.
Market Volume Estimates
- The volume of prescriptions in the US exceeds 300,000 annually.
- Globally, sales are expanding modestly, driven largely by demand in Europe and Asia.
Pricing Projections (2023–2028)
| Year |
Predicted Price Range (USD per 30 tablets) |
Key Factors |
| 2023 |
USD 15–USD 20 |
Market stabilization, high generic penetration |
| 2024 |
USD 12–USD 18 |
Continued pricing pressure, supply chain stability |
| 2025 |
USD 10–USD 15 |
Further generic competition, production efficiencies |
| 2026 |
USD 10–USD 13 |
Market maturity, consolidations among suppliers |
| 2027 |
USD 10–USD 12 |
Price stabilization, demand consistency |
| 2028 |
USD 10–USD 12 |
No major patent changes, mature market |
Factors Influencing Price Evolution
- Patent Expiration: No current patent protections limit steady generic competition.
- Regulatory Changes: Approval of biosimilar alternatives or reforms impacting pricing could influence costs.
- Market Expansion: Growing use in emerging markets may slightly alter prices through supply-demand shifts.
- Pricing Regulations: Price controls in certain countries could suppress profit margins.
Conclusion
NDC 00093-2210, representing benztropine mesylate, operates in a highly competitive generic market. Prices are expected to decline gradually, stabilizing around USD 10–USD 12 per 30 tablets by 2028. Market volume remains significant given the size of the Parkinson's disease patient base.
Key Takeaways
- Benztropine mesylate is primarily available as a generic, with low-cost options dominating the market.
- Prices have decreased substantially over the past decade due to competition, now averaging USD 15–USD 20 per 30 tablets.
- Projections indicate stabilization around USD 10–USD 12 per 30 tablets by 2028, barring regulatory or market disruptions.
- The growth of the market is mainly driven by demographic factors and the global burden of Parkinson's disease.
- Price pressures are likely to persist unless new formulations or patent protections alter current dynamics.
FAQs
-
What are the main factors influencing benztropine price changes?
Patent expirations, generic competition, manufacturing costs, and regional regulations.
-
How does the availability of generics impact market prices?
It drives prices downward due to increased supply and competition.
-
Are there upcoming patent protections or formulations that could alter prices?
No current patents; future formulations are unlikely to impact prices significantly without regulatory approval.
-
What markets beyond the US could influence global prices?
Europe and Asia, where Parkinson’s prevalence and healthcare infrastructure support increased drug access.
-
What is the potential for alternative therapies to replace benztropine?
Emerging treatments, such as newer dopaminergic agents and neuroprotective drugs, could impact long-term demand but are not expected to eliminate benztropine usage entirely.
Citations
[1] IQVIA. "United States Prescription Drug Data, 2022."
[2] Grand View Research. "Parkinson’s Disease Market Size & Overview," 2022.
[3] FDA. "Generic Drug Approvals and Patent Status," 2023.
[4] Medscape. "Benztropine: Brand and Generic Prices," 2023.
